[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569993":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":52,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":20,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":82,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Electrodermal Activity Measurement Subjects","EXPERIMENTAL","Participants will have their baseline electrodermal activity (EDA) response to pain measured as well as their EDA response measured while participating in a set of standardized functional tests.",[13],"Device: Electrodermal Activity signal",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Electrodermal Activity signal","Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Peter L Schilling, MD, MS","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Jon M Coordinator, MS","CONTACT","603-650-3306","jon.mikael.anderson@hitchcock.org",[32],{"facility":5,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Lebanon","New Hampshire","03756","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-72.25176,43.64229,{"lat":42,"lon":41},[45,48,49],{"name":46,"role":28,"phone":47,"phoneExt":20,"email":30},"Jon M Coordinator, MD, MS","603-653-3306",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"Brandon G Hill, MS","SUB_INVESTIGATOR",{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Peter L. Schilling","Assistant Professor of Orthopaedics, Geisel School of Medicine, Dartmouth",[56],{"name":57,"class":6},"University of Connecticut","100569993","measurement-of-osteoarthritic-patient-pain-through-electrodermal-activity-signals-100569993",false,"NCT06701461","Measurement of Osteoarthritic Patient Pain Through Electrodermal Activity Signals","Study subjects\n\nInclusion Criteria:\n\n* Kellgren-Lawrence Grade \\>= 3\n\nExclusion Criteria:\n\n* Inflammatory arthropathy (e.g., rheumatoid arthritis), BMI \\>=35\n\nControl subjects:\n\nExclusion Criteria:\n\n* Complaints of lower extremity joint pain\n* Known diagnosis of knee osteoarthpathy\n* Prior history of knee surgery, knee injections, or injury to knee joints (e.g., meniscus tears, ligamentous injuries), BMI \\>=35\n\nBoth groups, exclusion:\n\n* Subjects with chronic heart problems, including, but not limited to, chronic hypertension, heart palpitations, a weak or irregular heartbeat, or a previous heart attack,\n* Subjects taking the following drugs within 12 hours of the experiment or during the experiment: caffeine, alcohol, psychoactive drugs, nicotine or marijuana, other recreational drugs, and medicine of any kind that is not normally taken daily. Such medications include;\n\n  * NSAIDs\n  * Acetaminophen\n  * Steroidal anti-inflammatory agents\n  * Bronchodilators\n  * Appetite suppressants\n  * Lipase inhibitors\n* Women who are currently pregnant\n* Subjects with Raynaud's syndrome\n* Subjects with any of the following conditions: active skin lesions where EDA sensors are, vertigo or dizziness, and anyone with postural orthostatic tachycardia syndrome (POTS), peripheral neuropathy, seizure disorders, methicillin-resistant staphylococcus aureus (MRSA), impaired circulation, medical implants, open skin lesions, chronic eczema on hands where EDA and electrical stimulator's electrodes are attached, diabetes, and epilepsy.\n* Participants who have a skin sensitivity to metals, have a pacemaker or defibrillator, or have recent head trauma within the past two weeks (even without loss of consciousness)\n* Participants who cannot feel physical pain or have a history of self-harm",true,"ALL","50 Years","80 Years",{"count":69,"type":70},15,"ESTIMATED","INTERVENTIONAL",[73],"NA","This pilot study aims to investigate the viability of using a smartwatch-based electrodermal activity (EDA) sensor to capture enough EDA signal to quantitatively assess pain in osteoarthritis subjects and test the feasibility of its methods and procedures for later use in subsequent larger-scale studies.",[76],"Osteo Arthritis Knee",[78,79,80,81],"Pain","Electrodermal Activity Signals","Osteoarthritis","Knee","NOT_YET_RECRUITING","2026-03-04",{"date":85,"type":86},"2026-03-06","ACTUAL",{"date":88,"type":70},"2026-08",{"date":90,"type":70},"2026-10",{"name":5,"class":6},1]